




Nick Pavlakis
Chair, Scientific Advisory Committee

General Assembly
3 June 2016



Background

- Established 2004
- 580 members
- Multidisciplinary craft group representation



MISSION

To reduce the incidence, morbidity and mortality of lung and other thoracic cancers and improve the quality of life of patients, their carers and families in Australia and New Zealand by coordinating and facilitating high quality clinical research

OBJECTIVES

Develop and conduct high quality, clinically relevant investigator-led clinical trials

Translate research findings into clinical practice

Ensure the ALTG is a sustainable organisation

INITIATIVES

International collaborations – TACT

Interest-based subgroups

Broad portfolio of trials

Engage trainees and fellows

Efficient decision-making structures and processes

ALTG publications

Annual Scientific Meeting

Educational activities and workshops

Travel grants

Funding strategy


ALTG profile and awareness


Broad membership



Governance

- Legal entity: Lung Foundation Australia
- Brisbane, QLD






Office Bearers

- Management Advisory Committee (2 x 2 years)
 - President
 - Secretary
 - Treasurer
 - Past-President
 - Craft group representatives
 - Consumer representative
 - NZ representative
 - SAC Chair (appointed)

SAC Subgroups (n ≈ 8)

- Co-Chairs (2)
- ALTG members – interest/craft gp rep
- Research Fellow (1)



SAC Executive (n ≈ 10)

- SAC Chair **OR** Deputy Chair
- ALTG President **OR** ALTG Past-President
- Subgp Co-Chairs (agenda-driven; 1/subgp)
- Data centre rep
- ALTG Executive Officer
- Research Fellow (1)

SAC (n ≈ 15)

- SAC Chair
- SAC Deputy Chair
- ALTG President
- ALTG Past-President
- Subgroup Co-Chairs (1/subgp)
- CAP rep (2)
- Data centre rep
- ALTG Executive Officer
- Research Fellows

Trial Operations

- Funding for trials
 - Cancer Australia – concept development
 - NHMRC
 - Cancer Australia Priority-driven Collaborative Cancer Research Scheme
 - Industry
 - Donations and philanthropic funds (via LFA)
- Trial conduct
 - Trial coordinating centre
 - NHMRC Clinical Trials Centre (CTC)
 - Provides data centre and statistical support

Key Studies

- Actively enrolling trials
 - A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer (BR.31)
- Completed trials within last five years
 - A Double Blind Placebo Controlled Randomized Trial of PF-804 in Patients With Incurable Stage IIIB/IV Non-Small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease (BR.26)
 - A Phase III, randomised trial of adding nitroglycerin to first line chemotherapy for advanced non-small cell lung cancer (NITRO)
 - A Double Blind Randomized Trial of Cediranib Versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer (BR.29)

Intergroup Collaborations

- Successful collaboration with
 - NVALT
 - NCIC/CCTG

- NHMRC CTC (ALTG data centre) has collaborated with
 - EORTC
 - Japan
 - Korea
 - Taiwan
 - USA